Interv Akut Kardiol. 2022;21(1):19-26 | DOI: 10.36290/kar.2022.007

Stroke and/or transient ischemic attack prophylaxis from the perspective of an interventional cardiologist

Bronislav Janek
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Stroke is one of the most common causes of permanent disability and death in economically developed countries. Ischemic strokes and transient ischemic attacks account for 85% of all these events. The paper deals with two the main causes of central thromboembolism: non-valvular atrial fibrillation and paradoxical embolization with evidence of patent foramen ovale as well as the possibilities of catheterization treatment in their prophylaxis.

Keywords: stroke, prophylaxis, catheterization.

Received: February 15, 2022; Revised: February 27, 2022; Accepted: February 28, 2022; Prepublished online: February 28, 2022; Published: March 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janek B. Stroke and/or transient ischemic attack prophylaxis from the perspective of an interventional cardiologist. Interv Akut Kardiol. 2022;21(1):19-26. doi: 10.36290/kar.2022.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sedova P, Brown RD, Zvolsky M, et al. Incidence of Stroke and Ischemic Stro ke Subtypes: A Community­‑Based Study in Brno, Czech Republic. Cerebrovasc Dis [online]. 2021;50(1):54-61. doi.org/10.1159/000512180. ISSN 1015-9770 (print), 1421-9786. Go to original source... Go to PubMed...
    2. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of en evolving epidemic in 21st century. Int J Cardiol. 2013:167:1807-1824; https://doi: 10.1016/j.ijcardd.2012. 12. 093. Go to original source...
    3. vanWalraven C, Hart RG, Singer DE, Et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta­‑analysis. JAMA. 2002;288:241-48. doi:10.1001/jama.288. 19. 2441. Go to original source...
    4. Atrial Fibrillation Investigators. Ris factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57. Go to original source...
    5. Fiala M, Haman L, Čihák R. Doporučení ESC pro diagnostiku a léčbu fibrilace síní, 2020. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa. 2021;63:135-161. Go to original source...
    6. Al­‑Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function and role in thromboembolism. Heart. 1999:82:547-54. doi: 0.1136/hrt.82. 5. 547. Go to original source... Go to PubMed...
    7. Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investrigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a radnomized clinical trial. JAMA. 2014;312:1988-98. doi: 10.1001/jama.2014.15192. Go to original source... Go to PubMed...
    8. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long­‑term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12. doi: 10.1001/j.jacc.2014. 04. 029. Go to original source...
    9. Alkhouli M, Busu T, Shah K, et al. Incidence and Clinical Impact of Device­‑Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion. A Meta­‑Analysis. J Am Coll Cardiol EP. 2018;4:1629-37. doi.org/10.1016/j.jacep.2018. 09. 007. Go to original source... Go to PubMed...
    10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta­‑analysis of randomized trials. Lancet. 2014; 383:955-962. doi: 10.1016/SO140-6736(13)62343-0. Go to original source...
    11. Beyer­‑Westendorf J, Ehlken B, Evers T. Real­‑world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016; 18:1150-57. doi: 10.1093/europace/euv421. Go to original source... Go to PubMed...
    12. Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high­‑risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75:3122-35. doi.org/10.1016/j.jacc.2020. 04. 067. Go to original source... Go to PubMed...
    13. Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus non­‑warfarin oral anticoagulation in atrial fibrillation: 4-year outcomes of Prague-17. J Am Coll Cardiol. 2021. doi: 10.1016/j.jacc.2021. 10. 023. Go to original source...
    14. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guidelilne for the management of patients with atrial fibrillation: a report of ACC/AHA Task Force on Clinical Practice Guidelines adn th HRS in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-51. Go to original source... Go to PubMed...
    15. Hindrics G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation with the Eukropean Association for Cardio­‑Thoracic Surgery (EACTS): the Task Force for the diagonosis and management of atrial fibrillation of the ESC developer with the secial contribution of the European Heart Rythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. Go to original source... Go to PubMed...
    16. Lund J, Saunders CL, Edwards D, et al. Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study. Open Heart. 2021;8:e001737. Go to original source... Go to PubMed...
    17. Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE). Circulation. 2021;144:1543-1552. doi 10.1161/circulationaha.121-057063. Go to original source... Go to PubMed...
    18. Táborský M, Dušek L, Kautzner J, et al. SETAP: epidemiology and prevention of stroke and TIA in Czech patients with atrial fibrillation. Europace 2020. doi: 10.1093/euaa261. Go to original source...
    19. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation. European Heart Journal. 2005;26(22):2422-2434, https://doi.org/10.1093/eurheartj/ehi505. Go to original source... Go to PubMed...
    20. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991-99. Go to original source... Go to PubMed...
    21. Ma Y, Li D, Bai F, et al. Patent foramen ovale closure of medical therapy for secondary prevention of cryptogenic stroke. An update meta­‑analysis of randomized controlled trials. Medicine. 2018;97:34(e11965). Go to original source... Go to PubMed...
    22. Ntaios G, Papavasileiou V, Sagris D, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack. Updated systematic review and meta­‑analysis. Stroke. 2018;49:412-418. doi: 10.1161/strokeaha.117.020030. Go to original source... Go to PubMed...
    23. Varvařovský I, Mates M, Horák D, et al. Odborné stanovisko pro uzávěr otevřeného foramen ovale (PFO). Společný dokument České asociace intervenční kardiologie České kardiologické společnosti, České neurologické společnosti a České asociace kardiovaskulárních zobrazovacích metod České kardiologické společnosti.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.